Haemonetics (HAE) – Company Press Releases
-
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
-
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
-
Haemonetics Corporation Completes Acquisition of Attune Medical
-
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
-
Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference
-
Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day
-
Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024
-
Haemonetics Corporation Completes Acquisition of OpSens Inc.
-
Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
-
Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
-
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023
-
Haemonetics Announces European Expansion for VASCADE® Vascular Closure System
-
Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
-
Diane M. Bryant Joins Haemonetics' Board of Directors
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023
-
/C O R R E C T I O N -- Haemonetics Corporation/
-
Haemonetics Receives FDA Clearance for Enhancements to NexSys PCS® Plasma Collection System
-
Haemonetics 4th Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2023 Results: May 11, 2023
-
Haemonetics Publishes Inaugural Corporate Responsibility Report
-
Vivasure Medical Announces FDA IDE Approval to Initiate U.S. Pivotal Study
-
Haemonetics Introduces Next Generation "Intelligent Control" Software for Cell Saver® Elite®+ Autotransfusion System
-
Haemonetics to Present at Raymond James 44th Annual Institutional Investors Conference
-
Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023
-
Haemonetics to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Haemonetics 2nd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2023 Results: November 7, 2022
-
Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center
-
Haemonetics Earns CE Mark for VASCADE® Vascular Closure Product Portfolio
-
Haemonetics Announces Agreement to Offer Enhanced Transfusion Management Software to Epic's Global Network of Hospitals
-
Haemonetics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
Haemonetics 1st Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2023 Results: August 10, 2022
-
Haemonetics Completes Move to New Manufacturing Facility in Clinton, PA
-
Haemonetics Corporation Announces Additional Information Regarding Its Investor Day on June 29, 2022
-
Haemonetics 4th Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website
-
Haemonetics to Host Investor Day Event on June 29, 2022
-
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2022 Results: May 10, 2022
-
Haemonetics Appoints James D'Arecca Chief Financial Officer
-
Haemonetics to Present at Raymond James 43rd Annual Institutional Investors Conference
-
Haemonetics 3rd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2022 Results: February 8, 2022
-
Haemonetics Announces CFO William P. Burke's Retirement for June 2022
-
Haemonetics 2nd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website
-
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2022 Results: November 9, 2021
-
Haemonetics Announces VASCADE MVP® Venous Vascular Closure System Gains the First and Only FDA Approval for Same-Day Discharge Following Atrial Fibrillation Ablation
-
Haemonetics To Present At The 19th Annual Morgan Stanley Global Healthcare Conference
Back to HAE Stock Lookup